Prof. Cy Stein, MD, PhD
Prof. Dr. Cy Stein is Head of Medical Genitourinary Oncology and Professor of Medicine, Urology and Molecular Pharmacology at the Albert Einstein College of Medicine, New York. He also serves as an Attending Physician at the Montefiore Medical Center and is a Diplomate of nearly 20 years' standing of both the American Board of Internal Medicine and the American Board of Oncology.
Professor Stein is an internationally recognized innovator in the development of drugs based on antisense and RNA interference. In his distinguished career in research and treatment of cancers he has been involved for the past 15 years with leading preclinical and clinical trials of nucleic acid therapies. He is an editorial board member of Clinical Cancer Research, Molecular Cancer Therapeutics, Bioconjugate Chemistry and Cancer Gene Therapy, as well as Co-Editor of the journal Oligonucleotides (formerly Antisense and Nucleic Acid Drug Development) and has published over 150 papers in the field. Dr. Stein holds numerous patents related to experimental therapeutics with antisense and nucleic acids, and he is a world leader in this research area. He is currently on the scientific advisory boards of several companies including Genta and Atugen. Prof. Stein was a co-developer of Genta Inc's Genasense antisense drug for BCL-2-dependent breast cancer.
Prof Stein is a medical doctor and also has a PhD in chemistry. He is an oncologist and was trained at the New York Hospital/Cornell Medical Center and the National Institutes of Health. He was a professor at the College of Physicians and Surgeons at Columbia University for 13 years prior to taking up the chair at the Albert Einstein College. He is a pioneer in the research on anti-sense therapies against HIV/AIDS.
AI
